Putting patient perspectives at the heart of kidney cancer researchCommissioned by Ipsen. Ipsen’s Steven Hildemann looks at how we can harness the power of patient perspectives in Share XPutting patient perspectives at the heart of kidney cancer researchhttps://pharmaphorum.com/patients/patient-perspectives-kidney-cancer-research/
Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewPatients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo Share XScotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewhttps://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
BMS gets an important win for Opdivo combination in kidney cancerBristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the Share XBMS gets an important win for Opdivo combination in kidney cancerhttps://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
NICE rejects MSD/Pfizer’s combination in untreated kidney cancerNICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) Share XNICE rejects MSD/Pfizer’s combination in untreated kidney cancerhttps://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/
Immunicum continues cell therapy trials after positive kidney cancer readoutSweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it Share XImmunicum continues cell therapy trials after positive kidney cancer readouthttps://pharmaphorum.com/news/immunicum-to-push-on-with-immunotherapy/
Keytruda combo cleared as first-line kidney cancer treatment in EUMerck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in Share XKeytruda combo cleared as first-line kidney cancer treatment in EUhttps://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/
Immunicum shares fall despite “fantastic” kidney cancer dataShares in Swedish biotech Immunicum dipped sharply after it reported phase 2 results with its lead dendritic cell Share XImmunicum shares fall despite “fantastic” kidney cancer datahttps://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/
